Drugs / Selegiline
Selegiline
also known as
EMSAM · Selegiline Transdermal System · STS · Zelapar · Selegiline-hydrochloride · Selegiline-neuraxpharm
targets MAOB via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | EMSAM | — | 2014-09-10 | fda.gov ↗ |
| Approved | US (FDA) | SELEGILINE HYDROCHLORIDE | — | 1989-06-05 | fda.gov ↗ |
Trials 27 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00439413 Comparator | Jun 2007 → Aug 2008 | nicotine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT00531596 Comparator | Apr → Jul 2007 | — | Somerset Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00532116 Comparator | Apr → Aug 2007 | — | Somerset Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00282152 Background | Mar 2006 → Jan 2012 | Parkinson disease | Vanderbilt University Medical Center | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 35 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Selegiline | “Examples of drugs used include carbidopa/levodopa, pramipexole, ropinirole, and selegiline.” NCT00282152 ↗28“new orally disintegration tablet (ODT) formulation of selegiline, called ZelaparTM” NCT00640159 ↗ |
| Known as | EMSAM | “EMSAM (Selegiline Transdermal System) 6mg/24Hr” NCT00531596 ↗ |
| Known as | Selegiline Transdermal System | “OBJECTIVE: To assess the long-term safety (primary aim) and efficacy (secondary aim) of the MAO-B inhibitor Selegiline Transdermal System (STS) for the treatment of...” PMID 18042509 ↗ Nov 20071“Drug: Selegiline Transdermal System” NCT00531947 ↗ |
| Known as | Selegiline-hydrochloride | “Drug: Selegiline-hydrochloride” NCT05938517 ↗ |
| Known as | Selegiline-neuraxpharm | “Selegiline-neuraxpharm” NCT05938517 ↗ |
| Known as | STS | “OBJECTIVE: To assess the long-term safety (primary aim) and efficacy (secondary aim) of the MAO-B inhibitor Selegiline Transdermal System (STS) for the treatment of...” PMID 18042509 ↗ Nov 20071“This study examined the efficacy and safety of selegiline transdermal system (STS) and brief repeated behavioral intervention (BRBI) for smoking cessation in heavy smokers.” PMID 21846661 ↗ Aug 2011 |
| Known as | Zelapar | “new orally disintegration tablet (ODT) formulation of selegiline, called ZelaparTM” NCT00640159 ↗1“orally disintegrating selegiline (Zelapar)” NCT00443872 ↗ |
| Action | Inhibit | “MAO-B inhibitor” PMID 18042509 ↗ Nov 2007 |
| Route | Other | “the selegiline transdermal system (STS)” PMID 19890073 ↗ Nov 2009 |
| Target | MAOB | “the irreversible MAO-B inhibitor selegiline” PMID 40932155 ↗ Oct 2025 |